Hemlibra^TM - Update to Québec’s list of blood products, December 2019

To meet the needs of the Québec Ministry of Health and Social Services (MSSS), INESSS has developed an evaluation process for blood products with a view to their addition or refusal of their addition to Québec’s list of approved blood products (Liste des produits du système du sang du Québec).

This guidance supports INESSS’s recommendation that Hemlibra^TM (emicizumab) should not be offered as a treatment option for patients with hemophilia A without factor VIII (FVIII) inhibitors.